Ken Griffin Aadi Bioscience, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 28,538 shares of AADI stock, worth $48,799. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,538
Previous 2,600
997.62%
Holding current value
$48,799
Previous $4,000
1100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding AADI
# of Institutions
42Shares Held
30MCall Options Held
0Put Options Held
0-
Qvt Financial LP New York, NY4.62MShares$7.89 Million0.77% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.17MShares$7.12 Million0.25% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.7MShares$6.33 Million0.22% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA3.41MShares$5.83 Million14.49% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.85MShares$4.87 Million0.09% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $35.9M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...